PURPOSE: Fanconi anemia is a genetically heterogeneous chromosomal breakage disorder exhibiting a high degree of clinical variability. Clinical diagnoses are confirmed by testing patient cells for increased sensitivity to crosslinking agents. Fanconi anemia complementation group assignment, essential for efficient molecular diagnosis of the disease, had not been validated for clinical application before this study. The purpose of this study was (1) confirmation of the accuracy of Fanconi anemia complementation group assignment to Group A (FANCA) and (2) development of a rapid mutation detection strategy that ensures the efficient capture of all FANCA mutations. METHODS: Using fibroblasts from 29 patients, diagnosis of Fanconi anemia and assignment to complementation Group A was made through breakage analysis studies. FANCA coding and flanking sequences were analyzed using denaturing high pressure liquid chromatography, sequencing, and multiplex ligation-dependent probe amplification. Patients in which two mutations were not identified were analyzed by cDNA sequencing. Patients with no mutations were sequenced for mutations in FANCC, G, E, and F. RESULTS: Of the 56 putative mutant alleles studied, 89% had an identifiable FANCA pathogenic mutation. Eight unique novel mutations were identified. CONCLUSION: Complementation assignment to Group A was validated in a clinical laboratory setting using our FANCA rapid molecular testing strategy.
PURPOSE: Fanconi anemia is a genetically heterogeneous chromosomal breakage disorder exhibiting a high degree of clinical variability. Clinical diagnoses are confirmed by testing patient cells for increased sensitivity to crosslinking agents. Fanconi anemia complementation group assignment, essential for efficient molecular diagnosis of the disease, had not been validated for clinical application before this study. The purpose of this study was (1) confirmation of the accuracy of Fanconi anemia complementation group assignment to Group A (FANCA) and (2) development of a rapid mutation detection strategy that ensures the efficient capture of all FANCA mutations. METHODS: Using fibroblasts from 29 patients, diagnosis of Fanconi anemia and assignment to complementation Group A was made through breakage analysis studies. FANCA coding and flanking sequences were analyzed using denaturing high pressure liquid chromatography, sequencing, and multiplex ligation-dependent probe amplification. Patients in which two mutations were not identified were analyzed by cDNA sequencing. Patients with no mutations were sequenced for mutations in FANCC, G, E, and F. RESULTS: Of the 56 putative mutant alleles studied, 89% had an identifiable FANCA pathogenic mutation. Eight unique novel mutations were identified. CONCLUSION: Complementation assignment to Group A was validated in a clinical laboratory setting using our FANCA rapid molecular testing strategy.
Authors: Blanche P Alter; Neelam Giri; Sharon A Savage; June A Peters; Jennifer T Loud; Lisa Leathwood; Ann G Carr; Mark H Greene; Philip S Rosenberg Journal: Br J Haematol Date: 2010-04-30 Impact factor: 6.998
Authors: Elizabeth K Flynn; Aparna Kamat; Francis P Lach; Frank X Donovan; Danielle C Kimble; Narisu Narisu; Erica Sanborn; Farid Boulad; Stella M Davies; Alfred P Gillio; Richard E Harris; Margaret L MacMillan; John E Wagner; Agata Smogorzewska; Arleen D Auerbach; Elaine A Ostrander; Settara C Chandrasekharappa Journal: Hum Mutat Date: 2014-11 Impact factor: 4.878
Authors: Danielle C Kimble; Francis P Lach; Siobhan Q Gregg; Frank X Donovan; Elizabeth K Flynn; Aparna Kamat; Alice Young; Meghana Vemulapalli; James W Thomas; James C Mullikin; Arleen D Auerbach; Agata Smogorzewska; Settara C Chandrasekharappa Journal: Hum Mutat Date: 2017-11-22 Impact factor: 4.878
Authors: Nils W Engel; Simon Schliffke; Ulrich Schüller; Christian Frenzel; Carsten Bokemeyer; Christian Kubisch; Davor Lessel Journal: Front Oncol Date: 2019-05-22 Impact factor: 6.244